Verona Pharma said that it has initiated a Phase 2 clinical trial of its RPL554 PDE3/PDE4 inhibitor DPI. The study is expected to enroll 36 patients with moderate to severe COPD and will evaluate PK, efficacy, and safety.
Verona is developing RPL554 as nebulized, DPI, and MDI formulations for various indications, including COPD, asthma, and cystic fibrosis. Earlier this year, Verona reported positive results from a Phase 2 trial of nebulized RPL554 for the treatment of COPD.
Verona Pharma CEO Jan-Anders Karlsson commented, “Positive results using inhaler formulations could dramatically expand the clinical utility and commercial opportunity for RPL554 in the maintenance treatment of COPD and potentially broaden its use for other respiratory indications, such as asthma. With an estimated 5.4 million people using inhalers for the maintenance treatment of COPD in the US alone, and another one million patients using nebulized formulations, we believe it is important to understand how RPL554 works via these different delivery platforms in order to fully realize and leverage its clinical potential for patients with respiratory diseases. We look forward to building upon the positive results that have been garnered to date utilizing the nebulized formulation of RPL554.”
Read the Verona Pharma press release.
